By Carlo Martuscelli

 

AstraZeneca PLC (AZN.LN) said Monday that a phase 3 clinical trial of drug Imfinzi showed the drug was able to improve survival rates in patients with small-cell lung cancer.

The British pharmaceutical company said that Imfinzi combined with chemotherapy showed a clinically meaningful improvement in overall survival for patients with untreated extensive-stage small-cell lung cancer when compared with standard chemotherapy.

AstraZeneca said that the treatment reduced the risk of death by 27%, with a median overall survival of 13 months versus 10.3 months for the standard of care.

In the study, titled Caspian, 33.9% of patients treated with Imfinzi reached the 18-month survival mark, compared with 24.7% for chemotherapy alone.

Small-cell lung cancer is an aggressive and fast-spreading cancer.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

September 09, 2019 04:12 ET (08:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Astrazeneca Charts.